Phase 1b/2
DISEASE
A total of 46 patients were enrolled in the GC cohort and were treated at the RP2D in phase 1b/2. Twelve patients (26%) had received at least two prior lines of therapy and 15 (33%) had > 2 metastatic sites of disease (Table Among patients who received the RP2D in the efficacy-evaluable population (All 46 patients in the phase 1b/2 GC cohort treated at the RP2D experienced a TEAE, with grade ≥ 3 TEAEs occurring in 91% (